SCHEMBL565471

SCHEMBL565471

COc1ncccc1CNCC(C)C(=O)N(Cc1cc(Cl)c2c(c1)OCCCO2)CC(C)C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PROKR2 Q8NFJ6 5/20 0.70
MAPK8 P45983 1/20 0.32
ALDH1A1 P00352 2/20 0.32
PDCD1 Q15116 3/20 0.32
CD274 Q9NZQ7 3/20 0.32
HTR2A P28223 2/20 0.32
HTR2C P28335 2/20 0.32
HTR2B P41595 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
GLA P06280 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
P2RX7 Q99572 1/20 0.31
RAF1 P04049 1/20 0.31
MAP2K1 Q02750 1/20 0.31
PTGES O14684 1/20 0.31
NAMPT P43490 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL564884 0.88 PROKR2 (0.69) PROKR2ALDH1A1KDM4EMEN1HPGD
SCHEMBL565781 0.88 PROKR2 (0.69) PROKR2ALDH1A1KDM4EMEN1HPGD
SCHEMBL565414 0.87 PROKR2 (0.74) PROKR2MAPK8ALDH1A1KDM4EKMT2A
SCHEMBL564206 0.86 PROKR2 (0.75) PROKR2MAPK8
SCHEMBL565130 0.86 PROKR2 (0.73) PROKR2MAPK8ALDH1A1KDM4EMEN1
SCHEMBL565413 0.86 PROKR2 (0.69) PROKR2MAPK8ALDH1A1MEN1GAA
SCHEMBL565002 0.85 PROKR2 (0.68) PROKR2MAPK8ALDH1A1KDM4EMEN1
SCHEMBL564954 0.85 PROKR2 (0.66) PROKR2ALDH1A1KDM4EMEN1GLA
SCHEMBL565287 0.85 PROKR2 (0.72) PROKR2MAPK8ALDH1A1KDM4EMEN1
SCHEMBL565072 0.85 PROKR2 (0.70) PROKR2MAPK8ALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
WO-2010077976-A2 PROKINETICIN RECEPTOR ANTAGONISTS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof PROKR2, PROKR1, GIPR PROKR2 1/4885MAPK8 1270/4885ALDH1A1 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.